Analytical Data
-
Gene name
PDE10A
- Application
-
Alternative Names
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y233
-
Expression Region
Asn508~Asp779
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PDE10A (phosphodiesterase 10A) is a crucial enzyme in the regulation of intracellular signaling pathways by hydrolyzing cyclic nucleotides, specifically cyclic AMP (cAMP) and cyclic GMP (cGMP). Its expression is predominantly observed in the brain, particularly in striatal neurons, indicating its significant role in neurotransmission and various neurological functions. Alterations in PDE10A levels have been linked to several neuropsychiatric disorders, including schizophrenia and Huntington's disease, making it a potential therapeutic target. The research on recombinant PDE10A protein primarily focuses on understanding its structure, enzymatic activity, and interactions with specific inhibitors or activators. By generating and characterizing recombinant PDE10A, researchers aim to elucidate its physiological role and develop small-molecule modulators that can enhance or inhibit its activity, thereby providing new avenues for the treatment of neurological disorders. Furthermore, detailed studies on PDE10A can contribute to the broader understanding of cyclic nucleotide signaling mechanisms in the central nervous system, positioning it as a pivotal focus for drug discovery and development in neuropharmacology.
